Shouyao Holdings (Beijing) Co. LTD
15
3
3
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
13%
2 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors
Role: lead
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
Role: lead
A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China
Role: lead
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects
Role: lead
A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects
Role: lead
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Role: lead
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors
Role: lead
A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors
Role: lead
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Role: lead
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Role: lead
A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation
Role: lead
Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI
Role: lead
A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor
Role: lead
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
Role: lead
Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
Role: lead
All 15 trials loaded